Beauty giant L’Oréal, via its venture capital fund Bold, recently acquired a minority stake in Timeline, a Swiss biotech firm specializing in longevity. Founded in 2007 as a spin-off from EPFL, Timeline focuses on innovative solutions for longevity in food, beauty, and health.
One of Timeline’s key developments is the exclusive molecule ‘Mitopure,’ designed to revitalize mitochondria, the cell’s energy centers prone to age-related dysfunction. L’Oréal plans to integrate Mitopure into dietary supplements and skincare products.
While the investment amount remains undisclosed, it will empower Timeline to advance its technology, expand operations, and potentially collaborate further with L’Oréal.
Barbara Lavernos, Deputy CEO of L’Oréal and President of Research, Innovation, and Technology, expressed enthusiasm, stating, “Longevity adds a new dimension to beauty by preventing, correcting, and even reversing the aging cycle of skin, scalp, and hair.”
The pursuit of longevity is gaining traction in the beauty and wellness industry. Recently, Estée Lauder launched Skin Longevity, emphasizing product innovation, a longevity expert collective, and funding for a research program at the Stanford Center on Longevity.
L’Oréal’s strategic investment aligns with its commitment to innovation, aiming to meet the rising demand for anti-aging and longevity solutions. In the first nine months of 2023, L’Oréal reported a 9.4% revenue increase, reaching €30.57 billion.
